Curis Inc
CRIS Real Time Price USDRecent trades of CRIS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CRIS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$15,000 Jan 18, 2018 Issue: Economics/Economic Development
-
$10,000 Jul 16, 2017 Issue: Economics/Economic Development
-
$10,000 Apr 18, 2017 Issue: Economics/Economic Development
-
$10,000 Jan 19, 2017 Issue: Economics/Economic Development
-
$10,000 Oct 16, 2016 Issue: Economics/Economic Development
-
$10,000 Jul 17, 2016 Issue: Economics/Economic Development
-
$10,000 Apr 19, 2016 Issue: Economics/Economic Development
-
$10,000 Jan 17, 2016 Issue: Economics/Economic Development
-
$10,000 Oct 18, 2015 Issue: Economics/Economic Development
-
$10,000 Apr 19, 2015 Issue: Economics/Economic Development
-
$10,000 Jan 19, 2015 Issue: Economics/Economic Development
-
$10,000 Oct 11, 2014 Issue: Indian/Native American Affairs
Estimated quarterly lobbying spending
CRIS Revenue by Segment or Geography
New patents grants
-
Patent Title: Crystal forms of immunomodulators Mar. 18, 2025
-
Patent Title: Combination therapies for the treatment of cancer Dec. 31, 2024
-
Patent Title: Conjoint therapies for immunomodulation Aug. 20, 2024
-
Patent Title: Crystal forms of immunomodulators Mar. 26, 2024
-
Patent Title: Phosphoinositide 3-kinase inhibitor with a zinc binding moiety May. 23, 2023
-
Patent Title: Crystal forms of immunomodulators May. 09, 2023
-
Patent Title: Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Mar. 07, 2023
-
Patent Title: Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Mar. 01, 2022
-
Patent Title: Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety Feb. 01, 2022
-
Patent Title: Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Oct. 05, 2021
-
Patent Title: Crystal forms of immunomodulators Jun. 22, 2021
-
Patent Title: Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Jan. 19, 2021
-
Patent Title: Fused amino pyridine as hsp90 inhibitors Nov. 24, 2020
-
Patent Title: Compounds and compositions for treating hematological disorders Sep. 01, 2020
-
Patent Title: Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Jun. 09, 2020
-
Patent Title: Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Jan. 28, 2020
-
Patent Title: Fused amino pyridine as hsp90 inhibitors Oct. 01, 2019
-
Patent Title: Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Jul. 02, 2019
-
Patent Title: Hedgehog antagonists having zinc binding moieties Feb. 26, 2019
-
Patent Title: Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Oct. 30, 2018
-
Patent Title: Fused amino pyridine as hsp90 inhibitors Jul. 31, 2018
-
Patent Title: Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Aug. 08, 2017
-
Patent Title: Phosphoinositide 3-kinase inhibitor with a zinc binding moiety May. 23, 2017
-
Patent Title: Fused amino pyridine as hsp90 inhibitors Apr. 25, 2017
-
Patent Title: Fused amino pyridine as hsp90 inhibitors Aug. 02, 2016
-
Patent Title: Pyridyl inhibitors of hedgehog signalling Apr. 26, 2016
-
Patent Title: Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Feb. 02, 2016
-
Patent Title: Mediators of hedgehog signaling pathways, compositions and uses related thereto Nov. 03, 2015
-
Patent Title: Tyrosine kinase inhibitors containing a zinc binding moiety Oct. 27, 2015
-
Patent Title: Crystalline forms of fused amino pyridines as hsp90 inhibitors Oct. 06, 2015
-
Patent Title: Quinazoline based egfr inhibitors Aug. 18, 2015
-
Patent Title: Fused amino pyridine as hsp90 inhibitors May. 26, 2015
-
Patent Title: Quinazoline based egfr inhibitors containing a zinc binding moiety May. 05, 2015
-
Patent Title: Quinazoline based egfr inhibitors containing a zinc binding moiety Mar. 10, 2015
-
Patent Title: Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Dec. 09, 2014
-
Patent Title: Small organic molecule regulators of cell proliferation Oct. 07, 2014
-
Patent Title: Tartrate salts of quinazoline based egfr inhibitors containing a zinc binding moiety Sep. 30, 2014
-
Patent Title: Mediators of hedgehog signaling pathways, compositions and uses related hereto Aug. 26, 2014
-
Patent Title: Rna interference modulators of hedgehog signaling and uses thereof Aug. 12, 2014
-
Patent Title: Mediators of hedgehog signaling pathways, compositions and uses related thereto Jul. 08, 2014
-
Patent Title: Fused amino pyridines for the treatment of brain tumors May. 13, 2014
-
Patent Title: Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Apr. 29, 2014
-
Patent Title: Cdk inhibitors Apr. 08, 2014
-
Patent Title: Variant hhip1 protein and methods and uses thereof Jan. 07, 2014
-
Patent Title: Quinazoline based egfr inhibitors containing a zinc binding moiety Dec. 10, 2013
-
Patent Title: Fused amino pyridine as hsp90 inhibitors Nov. 19, 2013
-
Patent Title: Cdk inhibitors containing a zinc binding moiety Oct. 22, 2013
-
Patent Title: Formulation of quinazoline based egfr inhibitors containing a zinc binding moiety Aug. 27, 2013
-
Patent Title: Methods of inhibiting unwanted cell proliferation using an antibody that binds to sonic hedgehog and inhibits hedgehog signaling Jul. 16, 2013
-
Patent Title: Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Jun. 11, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CRIS
Recent picks made for CRIS stock on CNBC
ETFs with the largest estimated holdings in CRIS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CRIS stock a Buy, Sell, or Hold?
- What is the price target for $CRIS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CRIS stock?
- Who owns the most shares of $CRIS stock?
- What funds own $CRIS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CRIS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.